Navigation Links
Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
Date:10/15/2008

ed patients were end-stage and had no effective therapies available. JX-594 multiplies selectively within cancer cells, leading to their destruction. These newly created copies of JX-594 are then released and are able to infect and eradicate other tumor cells both locally and in distant sites in the body. This cycle of JX-594 replication, cancer cell destruction, release and spread is then repeated. Normal cells are not affected by JX-594 resulting in safety and tolerability. The poxvirus strain backbone of JX-594 has been used safely in millions of people as part of a worldwide vaccination program. This strain naturally targets cancer cells due to common genetic defects in cancer cells. JX-594 was engineered to enhance this natural safety and cancer-selectivity by deleting its thymidine kinase (TK) gene, thus making it dependent on the cellular TK expressed at persistently high levels in cancer cells. To enhance product efficacy, JX-594 is also engineered to express the GM-CSF protein. GM-CSF complements the cancer cell lysis work of the product candidate, leading to a cascade of events resulting in tumor necrosis, tumor vasculature shutdown and an anti-tumoral immune attack.

About Jennerex

Jennerex Biotherapeutics was established in San Francisco and in Ottawa in 2006 with Dr. David Kirn (CEO) in San Francisco and Dr. John Bell (CSO) from the Ottawa Health Research Institute/University of Ottawa. Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The company's lead product JX-594, currently in an international Phase 2 trial for primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common large market cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
2. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
3. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
4. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
5. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
6. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
7. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
10. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
11. CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015  Leadership speaker and business author Mary Kelly, Ph.D ., is helping members ... Photo - http://photos.prnewswire.com/prnh/20150420/199849 ... ... ... possible to run a successful medical practice without pulling your hair out of your head or ...
(Date:4/21/2015)... 21, 2015  The increase of diabetes due ... for self-monitoring blood glucose (SMBG) meters and strips ... potential for this market.  Availability of inexpensive generic ... profit margins. Photo - http://photos.prnewswire.com/prnh/20150417/199443 ... & Sullivan, US Self-monitoring Blood Glucose Market ...
(Date:4/21/2015)... April 21, 2015  GenVec, Inc. (NASDAQ: ... a research collaboration agreement with the Laboratory of ... Institute of Allergy and Infectious Diseases, National Institutes ... will utilize GenVec,s proprietary gorilla adenovirus vectors to ... the LMIV in order to create and test ...
Breaking Medicine Technology:Medical Group Managers Build Effective Practices with Strategies from Leadership Expert Mary Kelly 2Medical Group Managers Build Effective Practices with Strategies from Leadership Expert Mary Kelly 3Medical Group Managers Build Effective Practices with Strategies from Leadership Expert Mary Kelly 4Medical Group Managers Build Effective Practices with Strategies from Leadership Expert Mary Kelly 5Noninvasive Glucose Monitors Creates Convergence with the Digital Health Era 2Noninvasive Glucose Monitors Creates Convergence with the Digital Health Era 3Noninvasive Glucose Monitors Creates Convergence with the Digital Health Era 4GenVec Announces Collaboration with the Laboratory of Malaria Immunology & Vaccinology 2GenVec Announces Collaboration with the Laboratory of Malaria Immunology & Vaccinology 3
... acute coronary syndrome being managed with percutaneous coronary ... ... Feb. 21 Daiichi,Sankyo Company, Limited (TSE: 4568) and Eli Lilly ... and Drug Administration (FDA) accepted,and designated Priority Review for the New ...
... Rx, a drug delivery,company specializing in dissolving thin ... completed a pilot clinical study for its,thin film ... in the prevention and treatment of nausea and ... ondansetron was studied against,GlaxoSmithKline,s Zofran ODT(R) product. Based ...
Cached Medicine Technology:FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel 2FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel 3MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study 2MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study 3
(Date:4/21/2015)... Zane Benefits, the leader in individual ... publication of a new guide “Health Reimbursement Accounts in ... the health insurance industry, including how employers can use ... what is permitted when implementing an HRA. This simple, ... which HRAs are compliant this year. , According ...
(Date:4/21/2015)... 2015 Autocarsinsurancetips.com has released a new ... auto insurance plans by comparing quotes. , ... the best policies in their neighborhood. The insurance market ... best offer simply by comparing different plans. , ... car insurance quotes. Insurance brokerage websites like http://autocarsinsurancetips.com/ ...
(Date:4/21/2015)... has released a new blog post explaining the importance of ... on a uto insurance prices . , Drivers ... for advantageous auto insurance discounts. Clients can now review multiple ... will also help them get the best rates in their ... cost coverage is no longer difficult as there are multiple ...
(Date:4/21/2015)... LifeWings Partners LLC today announced a toolkit to ... safety programs by getting more support from their physicians. ... ways to get more physician support and engagement in ... Act, the new model of health care reimbursement is ... volume of services. Health care leaders feel an increased ...
(Date:4/21/2015)... April 21, 2015 When a bandage ... can result. In order to solve this problem two ... Bandaging. , This improved bandage helps a cut, burn, ... pain and enhances air exposure. The bandage is easy ... The original design was submitted to the St. Louis ...
Breaking Medicine News(10 mins):Health News:Online Auto Insurance Quotes Can Help Clients Save Money 2Health News:Auto Insurance Quotes Offer Excellent Security for A Car 2Health News:LifeWings Announces New Physician Engagement Toolkit to Help Hospitals Weather Serious Ramifications of the Affordable Care Act 2
... Legislation passed today by the Democratically-controlled Michigan House ... the pockets of personal injury lawyers at the ... of Commerce."By repealing Michigan,s lawsuit abuse protections, the ... Michigan becomes a lawsuit magnet," said Wendy Block, ...
... real-time communication tools like instant messenger, texts and mobile ... engage with physicians."A lot of people at our company ... sales executive in a roundtable discussion conducted by Best ... distracted by doing four things at once that the ...
... or chasing a cat causes many tumbles, CDC reports, , , ... be favored companions of many Americans, but they,re also apparently ... each year. , U.S. health officials report that 86,629 people ... people a day who wind up in hospital emergency rooms, ...
... Bill Puts Patient Health and Safety and ... The Generic Pharmaceutical Association (GPhA) released ... and CEO Kathleen Jaeger regarding the bipartisan ... Access to Life-Saving Medicine Act.""Momentum is skyrocketing ...
... used bacteria to strip the drink of carbs , , ... say they,ve developed a low-calorie, low-sugar vegetable juice for ... said it uses lactic acid-producing bacteria (LAB) to remove ... other nutrients. LAB, also known as probiotics, are used ...
... Three researchers at the Johns Hopkins University School of Medicine ... Medical Institute (HHMI). Xinzhong Dong, Ph.D., Joshua Mendell, M.D., Ph.D., ... but also become employees of HHMI, which will provide research ... "We are thrilled for Xinzhong, Josh and Sin for being ...
Cached Medicine News:Health News:Sales Force Effectiveness: Less Texting, More Engagement 2Health News:For All Their Plusses, Pets Pose a Risk for Falls, Too 2Health News:For All Their Plusses, Pets Pose a Risk for Falls, Too 3Health News:GPhA Statement on the Introduction of the Bipartisan Senate Biogenerics Consensus Bill: 'Promoting Innovation and Access to Life-Saving Medicine Act' 2Health News:Three Johns Hopkins researchers named Howard Hughes Medical Institute early career scientists 2
For the quantitative determination of triglycerides in serum. Linearity: 1000 mg/dl....
Alkaline phosphatase FS (IFCC). For determination of alkaline phosphatase (ALP) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
For the quantitative determination of alkaline phosphatase in human serum....
Intended for the quantitative determination of alkaline phosphatase activity in serum or plasma. Kinetic reaction. 405 nm wavelength. 830 U/L at 30C linearity. Single vial, dry powder reagent....
Medicine Products: